Understanding COVID-19 treatment effectiveness in Veterans

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to describe how COVID-19 therapies have been utilized among Veterans with mild to moderate disease during different periods of SARS-CoV-2 variant circulation. It will compare the demographic and clinical characteristics of Veterans who receive these therapies against those who do not. The first phase will inform the design of a second phase that will evaluate the effectiveness of various COVID-19 treatments and vaccines, as well as other respiratory viruses like RSV and influenza. The findings are expected to guide policy decisions regarding COVID-19 pharmacotherapies within the VA healthcare system and beyond.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Phase 1:

\- Veterans with a laboratory-confirmed positive test for SARS-CoV-2 or a diagnosis of COVID-19 documented at any time since the beginning of the pandemic in January 2020 to present

Phase 2:

* All Veterans alive and in Veterans Health Administration (VHA) care as of January 2018
* Specific exclusion/inclusion criteria and observation periods will be further defined for each sub-study (See outcomes/publications)

Exclusion Criteria:

* VA employees who are not enrollees

Where it's running

• VA Portland Health Care System, Portland, OR
  Portland, Oregon, United States Recruiting

Study contacts

• Study coordinator: Kristina L Bajema, MD
• Email: Kristina.Bajema@va.gov
• Phone: (503) 220-8262

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Monitoring and detection of influenza, RSV, and COVID-19 in adults with and without HIV in Lusaka

  This project will test methods to detect influenza, RSV, and COVID-19 in adults with and without HIV who have recent respiratory symptoms in Lusaka.

  Recruiting at 2 sites Centre for Infectious Disease Research in Zambia · Lusaka, Lusaka Province and 1 other locations · NCT07030075

• High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy

  This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT07926217

• Zelicapavir versus placebo in adults at high risk for severe RSV

  This study tests whether zelicapavir, taken by mouth, can help adults with RSV who are at high risk for severe disease compared to placebo.

  Recruiting at 4 sites Phase 2/3 Enanta Pharmaceuticals, Inc · Cape Coral, Florida and 3 other locations · NCT07908381

• Abbott ID NOW at the point of care for flu-like illness in long-term care facilities

  This trial tests whether the Abbott ID NOW rapid test at the point of care in long-term care facilities can help identify influenza sooner for residents 65 and older with fever and respiratory symptoms.

  Recruiting China Medical University Hospital · Taichung · NCT07846423

• Egg-based H5N8 influenza vaccine at multiple doses with or without adjuvant in healthy adults

  This trial tests whether an egg-based H5N8 flu vaccine, given at low to high doses with or without an adjuvant, is safe and can provoke a stronger immune response in healthy adults 18 and older.

  Recruiting at 16 sites Phase 1/2 Sanofi · Tempe, Arizona and 15 other locations · NCT07779408

• Immune Responses to RSV in Older Adults After Nasal RSV Challenge

  This study tests how the immune system responds to RSV in healthy adults aged 65–75 by giving them a controlled nasal infection in a monitored setting.

  Recruiting Imperial College London · London, London · NCT07713628

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.